| Functionally defined therapeutic targets in diffuse intrinsic pontine glioma CS Grasso, Y Tang, N Truffaux, NE Berlow, L Liu, MA Debily, MJ Quist, ... Nature medicine 21 (6), 555-559, 2015 | 636 | 2015 |
| Inferring causal molecular networks: empirical assessment through a community-based effort SM Hill, LM Heiser, T Cokelaer, M Unger, NK Nesser, DE Carlin, Y Zhang, ... Nature methods 13 (4), 310-318, 2016 | 242 | 2016 |
| A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent KG Halvorson, KL Barton, K Schroeder, KL Misuraca, C Hoeman, ... PloS one 10 (3), e0118926, 2015 | 81 | 2015 |
| The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma N Bharathy, NE Berlow, E Wang, J Abraham, TP Settelmeyer, JE Hooper, ... Science signaling 11 (557), eaau7632, 2018 | 59 | 2018 |
| A new approach for prediction of tumor sensitivity to targeted drugs based on functional data N Berlow, LE Davis, EL Cantor, B Séguin, C Keller, R Pal BMC bioinformatics 14, 1-20, 2013 | 41 | 2013 |
| A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs R Pal, N Berlow Biocomputing 2012, 351-362, 2012 | 38 | 2012 |
| IGF1R as a key target in high risk, metastatic medulloblastoma MN Svalina, K Kikuchi, J Abraham, S Lal, MA Davare, TP Settelmeyer, ... Scientific reports 6 (1), 27012, 2016 | 33 | 2016 |
| An integrated approach to anti-cancer drug sensitivity prediction N Berlow, S Haider, Q Wan, M Geltzeiler, LE Davis, C Keller, R Pal IEEE/ACM transactions on computational biology and bioinformatics 11 (6 …, 2014 | 31 | 2014 |
| IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma NE Berlow, MN Svalina, MJ Quist, TP Settelmeyer, V Zherebitskiy, ... PloS one 13 (4), e0193565, 2018 | 24 | 2018 |
| Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma N Bharathy, MN Svalina, TP Settelmeyer, MM Cleary, NE Berlow, ... Oncotarget 8 (38), 62976, 2017 | 24 | 2017 |
| Preclinical rationale for entinostat in embryonal rhabdomyosarcoma N Bharathy, NE Berlow, E Wang, J Abraham, TP Settelmeyer, JE Hooper, ... Skeletal Muscle 9, 1-10, 2019 | 22 | 2019 |
| Volasertib preclinical activity in high-risk hepatoblastoma D Kats, CA Ricker, NE Berlow, B Noblet, D Nicolle, K Mevel, ... Oncotarget 10 (60), 6403, 2019 | 21 | 2019 |
| Combination therapy design for maximizing sensitivity and minimizing toxicity K Matlock, N Berlow, C Keller, R Pal Proceedings of the 7th ACM International Conference on Bioinformatics …, 2016 | 20 | 2016 |
| Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma NE Berlow, R Rikhi, M Geltzeiler, J Abraham, MN Svalina, LE Davis, ... BMC cancer 19, 1-23, 2019 | 19 | 2019 |
| Fracturability index maps for fracture placement and design of shale reservoirs A Alzahabi, MY Soliman, NE Berlow, TM Spinner US Patent 10,480,289, 2019 | 19 | 2019 |
| Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma X Lian, D Kats, S Rasmussen, LR Martin, A Karki, C Keller, NE Berlow Acta neuropathologica communications 9 (1), 88, 2021 | 15 | 2021 |
| Defining the extracellular matrix of rhabdomyosarcoma X Lian, JS Bond, N Bharathy, SP Boudko, E Pokidysheva, JF Shern, ... Frontiers in oncology 11, 601957, 2021 | 15 | 2021 |
| Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species LE Davis, S Jeng, MN Svalina, E Huang, J Pittsenbarger, EL Cantor, ... Oncotarget 8 (44), 76241, 2017 | 15 | 2017 |
| Defining an embryonal rhabdomyosarcoma endotype CA Ricker, K Crawford, K Matlock, M Lathara, B Seguin, ER Rudzinski, ... Molecular Case Studies 6 (2), a005066, 2020 | 12 | 2020 |
| Undifferentiated small round cell sarcoma in a young male: a case report CA Ricker, NE Berlow, KA Crawford, T Georgopapadakos, AN Huelskamp, ... Molecular Case Studies 6 (1), a004812, 2020 | 12 | 2020 |
Charles KellerScientific Director, Children's Cancer Therapy Development Institute在 cc-tdi.org 的电子邮件经过验证
